PMID- 21352639
OWN - NLM
STAT- MEDLINE
DCOM- 20110930
LR  - 20220311
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 32
IP  - 2
DP  - 2011 Mar-Apr
TI  - Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus 
      azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis.
PG  - 151-8
LID - 10.2500/aap.2011.32.3439 [doi]
AB  - Olopatadine hydrochloride nasal spray 0.6% (OLO) and azelastine nasal spray 137 
      micrograms (AZE) are effective in treating allergic rhinitis and AZE is indicated 
      for nonallergic vasomotor rhinitis (VMR). This study evaluates the relative 
      safety and efficacy of OLO and AZE in patients with VMR. This randomized, 
      double-blind, parallel-group, multicenter study compared OLO (an investigational 
      use) with AZE over 14 days in patients (n = 129) >/=12 years of age with chronic 
      VMR. Efficacy included the severity of nasal symptom scores. Safety included 
      adverse events (AEs) and nasal examinations. Patient perceptions of treatment 
      satisfaction and changes in allergy condition were determined using the Treatment 
      Satisfaction Questionnaire for Medication and Patient Global Assessment scores. 
      In the OLO and AZE groups, reflective scores for individual nasal symptoms (nasal 
      congestion, rhinorrhea, postnasal drip, and sneezing) and total nasal VMR symptom 
      scores decreased significantly from baseline to day 14 (p < 0.05). No significant 
      between-group differences were observed (p > 0.05). No serious AEs were reported 
      in either group. Overall, 22 and 20 AEs were reported in the OLO and AZE groups, 
      respectively. The most common AE was taste disturbance, reported by three (5.3%) 
      and six (10.3%) patients in the OLO and AZE groups, respectively. Patients in 
      both groups reported similar treatment satisfaction scores and a majority of 
      patients in both groups perceived an overall improvement in their rhinitis 
      condition. OLO has a similar efficacy and safety profile to AZE for the 
      management of VMR in patients >/=12 years of age.
FAU - Lieberman, Phil
AU  - Lieberman P
AD  - Allergy and Asthma Care, Germantown, Tennessee 38138, USA. 
      phillieberman@hotmail.com
FAU - Meltzer, Eli O
AU  - Meltzer EO
FAU - LaForce, Craig F
AU  - LaForce CF
FAU - Darter, Amy L
AU  - Darter AL
FAU - Tort, Maria J
AU  - Tort MJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110223
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Dibenzoxepins)
RN  - 0 (Nasal Sprays)
RN  - 0 (Phthalazines)
RN  - 2XG66W44KF (Olopatadine Hydrochloride)
RN  - ZQI909440X (azelastine)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - Aged
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Dibenzoxepins/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Mucosa/drug effects
MH  - Nasal Sprays
MH  - Olopatadine Hydrochloride
MH  - Phthalazines/*therapeutic use
MH  - Rhinitis, Vasomotor/*drug therapy
MH  - Taste
MH  - Treatment Outcome
EDAT- 2011/03/01 06:00
MHDA- 2011/10/01 06:00
CRDT- 2011/03/01 06:00
PHST- 2011/03/01 06:00 [entrez]
PHST- 2011/03/01 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
AID - 3439 [pii]
AID - 10.2500/aap.2011.32.3439 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2011 Mar-Apr;32(2):151-8. doi: 10.2500/aap.2011.32.3439. 
      Epub 2011 Feb 23.